secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001558370-25-002117
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus supplements proxy for UDENYCA sale; discloses JPMorgan valuation & cash flow projections
--------------------------------------------------------------------------------

- Four shareholder complaints filed in NYC Supreme Court alleging proxy deficiencies; company denies merit.
- Voluntarily adds JPMorgan's selected transaction analysis: implied consideration ~$530M (base plus risk-adjusted earnout).
- Discloses UDENYCA unlevered free cash flow: $51M in 2025E, rising to $105M by 2029E, with revenue $186M in 2025E.
- Special meeting to approve sale to Intas Pharmaceuticals remains scheduled for March 11, 2025.
- Company believes no supplemental disclosures are legally required but provides them to avoid litigation delay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025002117/0001558370-25-002117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025002117/chrs-20250304x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer